Gossamer Bio Valuation Multiples

Gossamer Bio Overview

About Gossamer Bio

Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.

Founded

2015

HQ

Employees

145

Website

gossamerbio.com

Sectors

BiopharmaceuticalsBioTech

Financials (LTM)

Revenue: $40M

EBITDA: ($144M)

EV

$162M

Valuation Multiples

Multiples.vc

Start free trial

Gossamer Bio Financials

Gossamer Bio reported last 12-month revenue of $40M and negative EBITDA of ($144M).

In the same LTM period, Gossamer Bio generated $40M in gross profit, ($144M) in EBITDA losses, and had net loss of ($158M).

Gossamer Bio P&L

In the most recent fiscal year, Gossamer Bio reported revenue of $48M and EBITDA of ($158M).

Gossamer Bio expects next 12-month revenue of XXX and NTM EBITDA of XXX

Gossamer Bio Stock Performance

Gossamer Bio has current market cap of $96M, and enterprise value of $162M.

Gossamer Bio's stock price is $0.41.

Gossamer Bio Valuation Multiples

Gossamer Bio trades at 4.1x EV/Revenue multiple, and (1.1x) EV/EBITDA.

Gossamer Bio Financial Valuation Multiples

As of April 11, 2026, Gossamer Bio has market cap of $96M and EV of $162M.

Equity research analysts estimate Gossamer Bio's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Gossamer Bio has a P/E ratio of (0.6x).

Gossamer Bio Margins & Growth Rates

Gossamer Bio's revenue in the last 12 month declined by (28%).

Gossamer Bio's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $1.5M for the same period.

Gossamer Bio's rule of 40 is (481%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Gossamer Bio's rule of X is (577%) (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Gossamer Bio Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

Gossamer Bio M&A Activity

Gossamer Bio acquired XXX companies to date.

Last acquisition by Gossamer Bio was on XXXXXXXX, XXXXX. Gossamer Bio acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Gossamer Bio Investment Activity

Gossamer Bio invested in XXX companies to date.

Gossamer Bio made its latest investment on XXXXXXXX, XXXXX. Gossamer Bio invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).